An observational study in Schizophrenia, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Observational
This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 6,876 is above the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults diagnosed with schizophrenia in the United States with a prescription for KarXT identified in linked electronic health record and administrative claims data.
Exclusion Criteria:
Adults aged ≥18 years in the United States with at least one prescription for KarXT on or after September 24, 2024 identified in linked electronic health record and claims data.
Drug: KarXT (xanomeline and trospium)
As per product label
Number of all-cause and schizophrenia-related healthcare encounters per participant
Number of inpatient admissions, emergency room visits, urgent care visits, and outpatient visits identified from claims and EHR data. Schizophrenia-related encounters are defined as those with a primary diagnosis of schizophrenia using ICD-10-CM codes.
Time frame: Baseline and up to 6 months
Number of participants adherent to KarXT (proportion of days covered ≥80%)
Adherence measured using proportion of days covered (PDC), defined as total days of KarXT supply divided by total number of days in the follow-up period. Participants with PDC ≥80% are classified as adherent. Reported as number and percentage of participants meeting adherence criteria.
Time frame: Baseline and up to 6 months
Time to discontinuation of KarXT
Time from index date (first KarXT prescription) to discontinuation, defined as a gap of ≥45 consecutive days without KarXT supply.
Time frame: Baseline and up to 6 months
KarXT initial dose (index dose)
Distribution of index dose (50 mg/20 mg, 100 mg/20 mg, 125 mg/30 mg, or starter pack)
Time frame: Baseline
Number of of participants with dose increases or decreases
Time frame: Baseline and up to 6 months
Number of participants using concomitant antipsychotic and anticholinergic medications
Time frame: Baseline and up to 6 months
Number of participants with comorbidities
Time frame: Baseline and up to 6 months
Number of participants with gastrointestinal adverse events
Time frame: Baseline and up to 6 months
Number of participants with documented schizophrenia symptoms
Presence of positive and negative schizophrenia symptoms identified using natural language processing (NLP) of unstructured clinical notes, including hallucinations, delusions, disorganized thought, amotivation, avolition, anhedonia, asociality, alogia, and blunted affect.
Time frame: Baseline and up to 6 months
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb